Can-Fite BioPharma Ltd.

CANFAMEXHealthcare● Active

$3.08

+$0.00(+0.00%)

Market Cap$1657040

P/E Ratio—

52W High$23.4

52W Low$2.83

Avg Volume519K

Open$3.12

Beta0.01

Free Cash Flow Financials Revenue

Can-Fite BioPharma Ltd. (CANF) Free Cash Flow & Analysis

Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.

CANF · free cash flow · updated Jun 9, 2026

Core FCF metrics

CANF · FCF · TTM · margin & CAGR

Free cash flow was −$9.0M for FY2025 (fiscal year ending 2025-12-31), down 18.1% year-over-year

FY2025 Free Cash Flow−$9.0M▼ -18.1% YoY

Trailing 12M (TTM)−$8.4Mtrailing 4 quarters sum

FCF Margin< −999%−$9.0M ÷ revenue

3-Year CAGRN/AN/A — contains negative FCF

5-Year CAGRN/AN/A — contains negative FCF

FormulaFCF = Operating Cash Flow − Capital ExpendituresTTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /cash-flow-statement · SEC 10-K / 10-Q · USDUpdated: Jun 9, 2026

Annual free cash flow history

FCF ($B, upper) · YoY Growth % (lower)

Positive FCFNegative FCF

Free Cash Flow

YoY Growth %

Annual free cash flow data

CANF · free cash flow history · annual / quarterly

Fiscal YearOperating CFCapExFree Cash FlowYoY ChangeFCF Margin

FY2025Latest−$9.0M(0M)−$9.0M▼ 18.1%—

FY2024−$7.6M(0M)−$7.6M▲ +9.5%—

FY2023−$8.4M(0M)−$8.4M▲ +21.9%—

FY2022−$10.8M(0M)−$10.8M▼ 9.5%—

FY2021−$9.9M(0M)−$9.9M▲ +18.4%—

FCF = Operating Cash Flow − Capital Expenditures · CapEx shown as (negative) · Source: SEC filings via FMP

FCF valuation metrics

CANF · P/FCF · FCF yield · FCF per share

Can-Fite BioPharma Ltd. (CANF) reported negative free cash flow of −$0.01B. FCF-based valuation ratios are not meaningful when FCF is negative.

FCF Yield (TTM)

N/A

Free Cash Flow ÷ Market Cap

per FMP freeCashFlowYieldTTM definition

FCF per Share (TTM)

N/A

TTM FCF ÷ Shares Outstanding

Price / FCF

N/A

Share Price ÷ FCF per Share

EV / FCF (TTM)

N/A

Enterprise Value basis

FCF-based valuation ratios are only meaningful when free cash flow is positive. Negative FCF indicates capital expenditures exceeded operating cash flow.

Source: FMP /key-metrics-ttm · /cash-flow-statement Q · /income-statementFY2025 · 2025-12-31

Cash flow statement summary

CANF · cash flow statement · operating / investing / financing

For FY2025, Can-Fite BioPharma Ltd. generated −$9.0M in operating cash flow and spent 0M in capital expenditures, yielding −$9.0M in free cash flow.

Operating Activities

−$9.0M

Cash from core business operations

2025-12-31

Investing Activities

−$0.0M

CapEx, acquisitions & investments

2025-12-31

Financing Activities

+$9.7M

Buybacks, dividends & debt

2025-12-31

FCF FormulaOperating CF (−$9.0M) − |CapEx| (0M) = FCF (−$9.0M)

For the complete Operating / Investing / Financing line-item breakdown:

View Full Cash Flow Statement →

Free cash flow vs peers (Healthcare)

CANF vs peers · FCF

#CompanyFree Cash FlowYoYFCF MarginRelative

Can-Fite BioPharma Ltd.YOU

CANF

−$9.0M-18.1%-2210.1%

Loss

UnitedHealth Group Incorporated

UNH

$16.07B-22.4%3.6%

82%

Eli Lilly and Company

LLY

$8.97B+2065.6%13.8%

46%

Healthcare · Sorted by FCF · FMP /cash-flow-statementFull FCF Rankings →

About Free Cash Flow & Methodology

Can-Fite BioPharma Ltd. (CANF) reported free cash flow of −$9.0M for FY2025 (fiscal year ending 2025-12-31), down 18.1% year-over-year.

Can-Fite BioPharma Ltd. has reported negative free cash flow in recent periods, indicating capital expenditures have exceeded operating cash flow. Data available for 15 fiscal years.

Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.

Q&A and summaries align with SEC 10-K/10-Q cash flow disclosures and FMP /cash-flow-statement where noted.

Revenue Financial statements Net income Earnings Forecast Price history Market cap Cash on hand P/E ratio

Frequently asked questions

CANF free cash flow · 8 questions

Can-Fite BioPharma Ltd. free cash flow was −$9.0M for FY2025, down 18.1% year-over-year. On a trailing twelve-month (TTM) basis, free cash flow stands at −$8.4M.

CANF free cash flowCANF FCFCANF FCF 2025CANF free cash flow TTM

▸ Source: FMP /cash-flow-statement · US GAAP · Can-Fite BioPharma Ltd. · Can-Fite BioPharma Ltd. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 9, 2026